Ciclotiazide [DCIT] en es it fr

Ciclotiazide [DCIT] Brand names, Ciclotiazide [DCIT] Analogs

Ciclotiazide [DCIT] Brand Names Mixture

  • Zylet (0.5% loteprednol etabonate + 0.3% tobramycin)

Ciclotiazide [DCIT] Chemical_Formula

C14H16ClN3O4S2

Ciclotiazide [DCIT] RX_link

No information avaliable

Ciclotiazide [DCIT] fda sheet

Ciclotiazide [DCIT] msds (material safety sheet)

Ciclotiazide_[DCIT] MSDS

Ciclotiazide [DCIT] Synthesis Reference

No information avaliable

Ciclotiazide [DCIT] Molecular Weight

389.879 g/mol

Ciclotiazide [DCIT] Melting Point

227-228oC

Ciclotiazide [DCIT] H2O Solubility

No information avaliable

Ciclotiazide [DCIT] State

Solid

Ciclotiazide [DCIT] LogP

1.048

Ciclotiazide [DCIT] Dosage Forms

Tablets (oral, 5mg)

Ciclotiazide [DCIT] Indication

Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.

Ciclotiazide [DCIT] Pharmacology

Like other thiazides, cyclothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Cyclothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Cyclothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.

Ciclotiazide [DCIT] Absorption

No information avaliable

Ciclotiazide [DCIT] side effects and Toxicity

Oral LD50 in mouse is > 10000 mg/kg, and > 4000 mg/kg in rat. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.

Ciclotiazide [DCIT] Patient Information

Ciclotiazide [DCIT] Organisms Affected

Humans and other mammals